Dr. Day is renowned for his neuroscience and
business development accomplishments and Mr. Zindrick is
prominently recognized for his legal and corporate governance
experience
Aeromics, Inc. (“Aeromics” or “the Company”), a
privately-held, clinical-stage pharmaceutical company focused on
controlling cerebral edema, or brain swelling, for people affected
by disabling and life-threatening severe ischemic stroke, announced
today the appointments of Mark Day, Ph.D. and Thomas Zindrick, J.D.
to the Aeromics board of directors.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20180816005296/en/
Mark Day, Ph.D., director, president and
chief executive officer, Bioasis Technologies, Inc.
“Mark and Tom bring extensive leadership and drug development
experience to our board,” said Jeffrey P. Draime, chairman of the
board, Aeromics. “Both of these individuals have achieved
tremendous success in advancing medicine. Their backgrounds within
major pharmaceutical companies and biotech will add significant
value to our board. Their contributions will be important as we
move forward to the successful completion of our clinical
trials.”
Mark Day, Ph.D. is a director and the president and chief
executive officer at Bioasis Technologies Inc. (TSX.V:BTI;
OTCQB:BIOAF). Dr. Day also serves as adjunct associate professor at
Yale University. Dr. Day has more than 20 years of experience
working in the industry. He has developed business plans for
Alexion Pharmaceuticals, Wyeth, Glaxo Smith Kline (GSK) and
Bristol-Myers Squibb (BMS) in multiple functional areas ranging
from the development of external research discovery engines and
global scouting strategies to the creation of internal
venture/investment funds. He has established and managed more than
20 collaborations, mergers and acquisitions and licensing deals in
research and development (R&D) and business development. Dr.
Day was head of translational medicine neuroscience at Wyeth and
was the co-chair of the early development team. At Abbott, he was
responsible for translational imaging and biomarkers across the
R&D portfolios. At BMS, Dr. Day was instrumental in the
acquisition of iPierian and he has developed strategies that can
shorten evaluation periods by several months, leading to early
decisions regarding the advancement or early termination of the
evaluative processes. Dr. Day previously served as head, CNS
virtual discovery, at Purdue Pharma. Prior to joining Purdue
Pharma, he served as executive director, head of external research
and scouting, at Alexion Pharmaceuticals, Inc. He is widely
recognized for his expertise and success in the recognition,
evaluation and development of pipeline acquisition and
collaboration targets across several therapeutic areas. Dr. Day has
presented his evaluations and formal recommendations at the highest
corporate levels and has also participated in the resulting deal
negotiations, leading to several high-profile acquisitions and
collaborations. He has more than 60 peer-reviewed manuscripts on
translational medicine, impulsivity, stroke, cognitive dysfunction
in neurological and psychiatric illness such as Alzheimer’s
diseases and ADHD, including first authorships in Nature, Science,
Nature Neuroscience, Neuroimaging, Proceedings of the Royal
Society.
Dr. Day earned his bachelor of science degree in biological
psychology and his doctor of philosophy degree in neuroscience from
Cardiff University. He completed his post doctorate studies in
systems level neuroscience at The University of Edinburgh under
Professor Richard G. Morris, FRS., FRSE.
“I am absolutely delighted to join the board of Aeromics at such
an exciting time for the company. Their Phase 1 is progressing
well, and the company’s novel approach to the treatment of CNS
edema and stroke has the potential to radically change the
prognosis of these diseases and significantly treat and improve
lives of patients and their caregivers,” said Dr. Day. “One of the
wonderful attributes of the Aeromics approach is the simplicity of
their scientific story. In a nutshell, by simply blocking water
from entering the CNS, via aquaporin 4 blockade, they have an
excellent shot on goal. I look forward to working with the board,
Marc Pelletier and his management team to help shape a successful
development path.”
Thomas Zindrick, J.D. is the president and chief
executive officer of Genelux Corporation, a clinical-stage
biopharmaceutical company. He is a distinguished life sciences and
biotechnology executive with a career spanning more than 25 years.
Mr. Zindrick joined Genelux Corporation in May 2014 after retiring
from Amgen, Inc. where he built his 16-year career. He has also
served as chief executive officer of Amitech Therapeutic Solutions,
Inc., a La Jolla, Calif.-based discovery and drug development
company focused on commercializing allosteric kinase
inhibitors.
During his career at Amgen, Mr. Zindrick held positions of
increasing responsibility, including vice president, associate
general counsel and chief compliance officer. As vice president,
associate general counsel, Mr. Zindrick led intellectual property,
licensing and regulatory law teams, and served on cross-functional
business and product development teams. These teams were
responsible for acquisitions totaling over $20 billion and the
licensing and development of six therapeutic products and numerous
clinical candidates. As chief compliance officer, he reported to
the board of directors and led the corporate compliance program,
which oversaw the compliance activities of numerous company
functions including product development, manufacturing and
marketing. Prior to joining Amgen, Mr. Zindrick was an attorney at
The Dow Chemical Company.
Mr. Zindrick earned his juris doctor degree from the University
of Illinois College of Law and a bachelor of arts degree in biology
from North Central College in Naperville, Ill.
“I am thrilled to join the board of Aeromics and look forward to
partnering with Marc and his team,” said Mr. Zindrick. “I am
pleased to be in a position to help bring this desperately needed
therapy to patients and physicians.”
ABOUT STROKE
Every 50 seconds someone in the United States suffers from a
stroke. Roughly 800,000 strokes are seen in the U.S. each year, of
which approximately 692,000 are acute ischemic strokes. An
estimated 140,000 patients with large hemispheric infarction suffer
life-threatening and severely disabling cerebral edema, or brain
swelling, and may benefit from an anti-edema medication.
ABOUT AER-271
AER-271 is a patented, intravenous (IV) prodrug that delivers
AER-270, a potent inhibitor of Aquaporin-4 (AQP4) water channels,
to the neurovascular unit. These channels are the primary route of
water movement into the central nervous system (CNS) under
conditions of ischemia. The osmotic imbalance and subsequent influx
of water via AQP4 occurs as a result of a lack of oxygen and leads
to edema (swelling), midline shift, increased intracranial pressure
and brain herniation resulting in permanent disability or death.
AER-271 is an investigational drug and is not approved by the U.S.
Food and Drug Administration.
ABOUT AEROMICS, INC.
Aeromics is a privately-held, clinical-stage pharmaceutical
company developing a first-in-class anti-edema therapy to treat
patients affected by acute central nervous system edema as a
consequence of large hemispheric infarction. A paradigm shift in
the understanding of water physiology was the discovery aquaporins,
proteins that form water channels to allow water in and out of
cells, by Peter Agre (2003 Nobel Prize in Chemistry). Despite the
vital role of aquaporins in maintaining water homeostasis and its
implications in various disease states, therapeutic agents
targeting aquaporins have remained elusive until now. Aeromics was
founded in 2006 by Marc F. Pelletier, M.Sc., Ph.D. and Walter
F. Boron M.D., Ph.D., both Yale University
scientists. Aeromics maintains headquarters in Branford, Conn. with
offices in Cleveland, Ohio. For more information, please visit:
https://www.aeromics.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180816005296/en/
Aeromics, Inc.Marc F. Pelletier, Ph.D.,
216-633-6708marc.pelletier@aeromics.com
BiOasis Technologies (TSXV:BTI)
Historical Stock Chart
From Mar 2024 to Apr 2024
BiOasis Technologies (TSXV:BTI)
Historical Stock Chart
From Apr 2023 to Apr 2024
